Financial News

Merck to acquire San Diego biotech company Prometheus Biosciences for $10.8 billion

Under the terms of the deal announced Sunday, Merck (NYSE: MRK) will acquire Prometheus Biosciences (NASDAQ: RXDX) for $200 per share in cash.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback